Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Analog peptides represent a promising tool to further optimize peptide-based vaccines in promoting the expansion of tumor antigen-specific cytotoxic T lymphocytes. Here, we report the results of a pilot trial designed to study the immunogenicity of the analog peptide NY-ESO-1 157-165V in combination with CpG 7909/PF3512676 and Montanide ISA 720 in patients with stage III/IV NY-ESO-1-expressing melanoma. Eight patients were immunized either with Montanide and CpG (arm 1, 3 patients); Montanide and peptide NY-ESO-1 157-165V (arm 2, 2 patients); or with Montanide, CpG, and peptide NY-ESO-1 157-165V (arm 3, 3 patients). Only the 3 patients immunized with Montanide, CpG, and peptide NY-ESO-1 157-165V in arm 3 developed a rapid increase of effector-memory NY-ESO-1-specific CD8+ T cells, detectable ex vivo. The majority of these cells exhibited an intermediate/late-stage differentiated phenotype (CD28-). Our study further demonstrated that our vaccine approach stimulated spontaneous tumor-reactive NY-ESO-1-specific CD8+ T cells in 2 patients with advanced disease, but failed to prime tumor-reactive NY-ESO-1-specific T cells in 1 patient with no spontaneously tumor-induced CD8+ T-cell responses to NY-ESO-1. Collectively, our data support the capability of the analog peptide NY-ESO-1 157-165V in combination with CpG and Montanide to promote the expansion of NY-ESO-1-specific CD8+ T cells in patients with advanced cancer. They also suggest that the presence of tumor-induced NY-ESO-1-specific T cells of well-defined clonotypes is critical for the expansion of tumor-reactive NY-ESO-1-specific CD8+ T cells after peptide-based vaccine strategies.
Fourcade
Julien
J
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213-2582, USA.
Kudela
Pavol
P
Andrade Filho
Pedro A
PA
Janjic
Bratislav
B
Land
Stephanie R
SR
Sander
Cindy
C
Krieg
Arthur
A
Donnenberg
Albert
A
Shen
Hongmei
H
Kirkwood
John M
JM
Zarour
Hassane M
HM
D000368:Aged; D000369:Aged, 80 and over; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007114:Immunization; D008297:Male; D008353:Mannitol / Q000031:analogs & derivatives / Q000627:therapeutic use; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology / Q000627:therapeutic use*; D009829:Oleic Acids / Q000627:therapeutic use; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use*; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism
D019496:Cancer Vaccines; D009363:Neoplasm Proteins; D009829:Oleic Acids; D009838:Oligodeoxyribonucleotides; D010446:Peptide Fragments; C483020:ProMune; C504237:peptide NY-ESO-1 157-165; C001681:mannide monooleate; D008353:Mannitol
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52
17517626
Nat Med. 2004 Sep;10(9):909-15
15340416
PLoS Med. 2004 Nov;1(2):e28
15578105
J Invest Dermatol. 1996 Jul;107(1):63-7
8752841
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s
16609053
Cancer Res. 2006 Feb 15;66(4):1912-6
16488988
Nat Med. 2002 Apr;8(4):379-85
11927944
J Immunol. 2007 Apr 1;178(7):4112-9
17371966
Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s
11300471
J Immunol. 1996 Sep 15;157(6):2539-48
8805655
J Immunother. 2004 Nov-Dec;27(6):472-7
15534491
J Exp Med. 2005 Apr 18;201(8):1243-55
15837811
Cancer Res. 2004 Feb 1;64(3):1140-5
14871849
J Immunother. 2005 May-Jun;28(3):252-7
15838382
Annu Rev Immunol. 2002;20:709-60
11861616
Eur J Immunol. 1992 May;22(5):1261-9
1533591
Cancer Res. 2000 Aug 15;60(16):4499-506
10969798
Nature. 2000 Dec 7;408(6813):740-5
11130078
Nature. 1999 Oct 14;401(6754):708-12
10537110
J Immunol. 2003 Feb 15;170(4):1822-9
12574347
Cancer Res. 2000 Sep 1;60(17):4946-52
10987311
J Immunol. 2000 Jul 15;165(2):948-55
10878370
J Exp Med. 1999 Jun 7;189(11):1757-64
10359579
J Clin Invest. 2005 Mar;115(3):739-46
15696196
Int J Cancer. 2006 Jul 15;119(2):317-27
16482562
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
9050879
J Exp Med. 1998 Jan 19;187(2):265-70
9432985
J Exp Med. 1998 Apr 20;187(8):1349-54
9547346
Annu Rev Immunol. 2006;24:175-208
16551247
Int J Cancer. 2007 Nov 1;121(9):2042-8
17640060
Int Immunol. 1999 Dec;11(12):1971-80
10590263